Bespoke rare disease pharmaceutical services
Expanding into the European market with rare disease drugs presents unique challenges – but we’re here to help. As a leading European life sciences organisation with over 30 years of experience specialising in rare disease drugs, we provide end-to-end rare disease commercialisation and consulting services to make sure your treatment reaches the patients who need it most.
An end-to-end solution for your specific needs in three steps
Finding patients
At Sciensus, we don’t just follow a one-size-fits-all approach.
We tailor our patient-finding strategies to match the unique characteristics of each rare disease and drug.
- In-country engagement with healthcare professionals and patient organisations to improve early diagnosis
- Targeted outreach programmes and peer-to-peer education to raise awareness
- Real-world data collection to refine market strategies
Accessing patients
Navigating the complex healthcare landscape to make it as smooth as possible.
We provide rare disease pharmaceutical services that enable timely access to treatments, even before full commercialisation. This in turn allows for the navigation of a complex healthcare landscape to be as smooth as possible.
- Expert regulatory understanding and extensive knowledge of early access opportunities
- Efficient supply chain management to deliver products safely and on time
- Regulatory support to streamline approvals and compliance
Supporting patients
Our Patient Support Programmes (PSP) make certain that patients and caregivers receive ongoing support, improving overall health outcomes and treatment adherence.
- Personalised digital and face-to-face interventions by experienced healthcare professionals
- Monitoring and collection of Patient and Clinician Reported Outcomes to generate real-world data
- Continuous engagement to optimise long-term patient care
Sciensus’ rare diseases consulting services
Expanding a rare disease drug into the European market requires expert navigation of regulatory pathways, patient access strategies, and commercialisation challenges. Sciensus provides tailored rare diseases consulting services, helping pharmaceutical companies secure regulatory approvals, implement Expanded Access Programmes, optimise supply chains, and engage with hard-to-reach patient populations. Our end-to-end support makes sure your treatment reaches the right patients – efficiently and compliantly.
Expertise
Scalability
Local access
Multilingual team
Transform market challenges into opportunities
With Sciensus as your rare diseases consulting services partner, you can confidently expand into the European market, ensuring that patients receive life-changing treatments without unnecessary delays.
Ready to bring your rare disease treatment to Europe?
Learn more about our services from our expert team
Figures behind the facts
With over 30 years of experience collaborating with US biotech companies to offer turnkey solutions for finding and assisting patients in Europe, we are ready to go. At pace.
$ 0
orphan drugs bought and sold per year
0
relationships with healthcare providers
0
units of orphan medicine supplied
Answering your questions
What are the biggest challenges in commercialising rare disease drugs in Europe?
Expanding into the European market involves navigating complex regulations, securing early patient access, optimising supply chains, and patient engagement. Sciensus provides rare diseases consulting services to simplify this process, helping pharmaceutical companies overcome these barriers efficiently.
How does Sciensus help pharma companies find rare disease patients?
We use a customised, data-driven approach that includes strategic collaboration with patient organisations, physician education, real-world data collection, and targeted outreach programmes. By reducing diagnosis times and improving patient identification, we help accelerate access to treatment.
What is an Expanded Access Programme (EAP) and how can Sciensus assist?
An Expanded Access Programme (EAP) allows patients to access investigational treatments before full regulatory approval. Sciensus helps pharmaceutical companies develop and execute EAPs across Europe, ensuring regulatory compliance, efficient patient access, and seamless distribution.
How does Sciensus ensure regulatory compliance in different European countries?
With in-depth regulatory expertise across multiple European markets, we work closely with local authorities to ensure rare disease drugs meet all necessary approval requirements. Our team stays updated on regulatory changes to streamline the approval process for our partners.
What patient support services does Sciensus provide?
Our Patient Support Programmes (PSP) include multilingual healthcare professional-led interventions, treatment adherence support, real-world data collection, and caregiver assistance. These programmes improve patient outcomes and enhance treatment success.
